Compare Stocks

4 / 10
Try these comparisons:

Stock Comparison

IQV vs PRA vs UNH vs CRL

Revenue, margins, valuation, and 5-year total return — side by side.

Live fundamentals10-year financials5-year price chart
IQV
IQVIA Holdings Inc.

Medical - Diagnostics & Research

HealthcareNYSE • US
Market Cap$30.32B
5Y Perf.+19.5%
PRA
ProAssurance Corporation

Insurance - Property & Casualty

Financial ServicesNYSE • US
Market Cap$1.27B
5Y Perf.+78.3%
UNH
UnitedHealth Group Incorporated

Medical - Healthcare Plans

HealthcareNYSE • US
Market Cap$335.60B
5Y Perf.+21.3%
CRL
Charles River Laboratories International, Inc.

Medical - Diagnostics & Research

HealthcareNYSE • US
Market Cap$8.98B
5Y Perf.+1.3%

IQV vs PRA vs UNH vs CRL — Key Financials

Market cap, revenue, margins, and valuation side-by-side.

Company Snapshot
IQV logoIQV
PRA logoPRA
UNH logoUNH
CRL logoCRL
IndustryMedical - Diagnostics & ResearchInsurance - Property & CasualtyMedical - Healthcare PlansMedical - Diagnostics & Research
Market Cap$30.32B$1.27B$335.60B$8.98B
Revenue (TTM)$16.63B$1.08B$449.71B$4.03B
Net Income (TTM)$1.39B$65M$12.04B$-185M
Gross Margin26.1%25.5%18.8%24.9%
Operating Margin13.9%8.4%4.2%11.8%
Forward P/E14.1x21.8x20.2x16.4x
Total Debt$16.17B$435M$78.39B$3.07B
Cash & Equiv.$1.98B$36M$24.36B$214M

IQV vs PRA vs UNH vs CRLLong-Term Stock Performance

Price return indexed to 100 at period start. Dividends excluded.

IQV
PRA
UNH
CRL
StockMay 20May 26Return
IQVIA Holdings Inc. (IQV)100119.5+19.5%
ProAssurance Corpor… (PRA)100178.3+78.3%
UnitedHealth Group … (UNH)100121.3+21.3%
Charles River Labor… (CRL)100101.3+1.3%

Price return only. Dividends and distributions are not included.

Quick Verdict: IQV vs PRA vs UNH vs CRL

Each card shows where this stock fits in a portfolio — not just who wins on paper.

Bottom line: IQV leads in 3 of 7 categories, making it the strongest pick for valuation and capital efficiency and profitability and margin quality. UnitedHealth Group Incorporated is the stronger pick specifically for growth and revenue expansion and dividend income and shareholder returns. PRA and CRL also each lead in at least one category. This set spans 2 sectors — these stocks serve different portfolio roles, not just different price points.
IQV
IQVIA Holdings Inc.
The Value Play

IQV carries the broadest edge in this set and is the clearest fit for value and quality.

  • Lower P/E (14.1x vs 16.4x)
  • 8.3% margin vs CRL's -4.6%
  • 4.7% ROA vs CRL's -2.5%, ROIC 8.7% vs 6.3%
Best for: value and quality
PRA
ProAssurance Corporation
The Insurance Pick

PRA is the clearest fit if your priority is sleep-well-at-night and defensive.

  • Lower volatility, beta 0.05, Low D/E 32.2%, current ratio 1.33x
  • Beta 0.05, current ratio 1.33x
  • Beta 0.05 vs CRL's 1.52, lower leverage
Best for: sleep-well-at-night and defensive
UNH
UnitedHealth Group Incorporated
The Insurance Pick

UNH is the #2 pick in this set and the best alternative if income & stability and growth exposure is your priority.

  • Dividend streak 25 yrs, beta 0.59, yield 2.4%
  • Rev growth 11.8%, EPS growth -14.7%, 3Y rev CAGR 11.4%
  • 220.6% 10Y total return vs IQV's 166.5%
  • 11.8% revenue growth vs PRA's -2.7%
Best for: income & stability and growth exposure
CRL
Charles River Laboratories International, Inc.
The Momentum Pick

CRL is the clearest fit if your priority is momentum.

  • +32.8% vs UNH's -3.2%
Best for: momentum
See the full category breakdown
CategoryWinnerWhy
GrowthUNH logoUNH11.8% revenue growth vs PRA's -2.7%
ValueIQV logoIQVLower P/E (14.1x vs 16.4x)
Quality / MarginsIQV logoIQV8.3% margin vs CRL's -4.6%
Stability / SafetyPRA logoPRABeta 0.05 vs CRL's 1.52, lower leverage
DividendsUNH logoUNH2.4% yield; 25-year raise streak; the other 3 pay no meaningful dividend
Momentum (1Y)CRL logoCRL+32.8% vs UNH's -3.2%
Efficiency (ROA)IQV logoIQV4.7% ROA vs CRL's -2.5%, ROIC 8.7% vs 6.3%

IQV vs PRA vs UNH vs CRL — Revenue Breakdown by Segment

How each company's revenue is distributed across its business units

IQVIQVIA Holdings Inc.
FY 2025
Research And Development Solutions
54.5%$8.9B
Technology And Analytics Solutions
40.6%$6.6B
Contract Sales And Medical Solutions
4.8%$788M
PRAProAssurance Corporation
FY 2025
Specialty Property and Casualty
77.5%$724M
Workers' Compensation Insurance Segment
17.6%$164M
Segregated Portfolio Cell Reinsurance
4.9%$46M
UNHUnitedHealth Group Incorporated
FY 2025
Unitedhealthcare
94.4%$332.4B
Optumhealth
5.6%$19.8B
CRLCharles River Laboratories International, Inc.
FY 2025
Discovery and Safety Assessment
59.8%$2.4B
Research Models and Services
21.1%$846M
Manufacturing Support
19.1%$766M

IQV vs PRA vs UNH vs CRL — Financial Metrics

Side-by-side numbers across 4 stocks — who leads on profitability, valuation, growth, and risk.

BEST OVERALLIQVLAGGINGCRL

Income & Cash Flow (Last 12 Months)

IQV leads this category, winning 5 of 6 comparable metrics.

UNH is the larger business by revenue, generating $449.7B annually — 416.7x PRA's $1.1B. IQV is the more profitable business, keeping 8.3% of every revenue dollar as net income compared to CRL's -4.6%. On growth, IQV holds the edge at +8.4% YoY revenue growth, suggesting stronger near-term business momentum.

MetricIQV logoIQVIQVIA Holdings In…PRA logoPRAProAssurance Corp…UNH logoUNHUnitedHealth Grou…CRL logoCRLCharles River Lab…
RevenueTrailing 12 months$16.6B$1.1B$449.7B$4.0B
EBITDAEarnings before interest/tax$3.5B$101M$23.2B$757M
Net IncomeAfter-tax profit$1.4B$65M$12.0B-$185M
Free Cash FlowCash after capex$2.7B-$17M$19.7B$391M
Gross MarginGross profit ÷ Revenue+26.1%+25.5%+18.8%+24.9%
Operating MarginEBIT ÷ Revenue+13.9%+8.4%+4.2%+11.8%
Net MarginNet income ÷ Revenue+8.3%+6.0%+2.7%-4.6%
FCF MarginFCF ÷ Revenue+16.1%-1.6%+4.4%+9.7%
Rev. Growth (YoY)Latest quarter vs prior year+8.4%-2.0%+2.0%+1.2%
EPS Growth (YoY)Latest quarter vs prior year+15.0%+2.5%+0.7%-160.0%
IQV leads this category, winning 5 of 6 comparable metrics.

Valuation Metrics

IQV leads this category, winning 3 of 6 comparable metrics.

At 22.8x trailing earnings, IQV trades at a 18% valuation discount to UNH's 27.9x P/E. On an enterprise value basis, IQV's 13.0x EV/EBITDA is more attractive than PRA's 19.5x.

MetricIQV logoIQVIQVIA Holdings In…PRA logoPRAProAssurance Corp…UNH logoUNHUnitedHealth Grou…CRL logoCRLCharles River Lab…
Market CapShares × price$30.3B$1.3B$335.6B$9.0B
Enterprise ValueMkt cap + debt − cash$44.5B$1.7B$389.6B$11.8B
Trailing P/EPrice ÷ TTM EPS22.79x24.86x27.95x-62.52x
Forward P/EPrice ÷ next-FY EPS est.14.06x21.76x20.19x16.42x
PEG RatioP/E ÷ EPS growth rate0.56x
EV / EBITDAEnterprise value multiple12.97x19.46x16.70x12.98x
Price / SalesMarket cap ÷ Revenue1.86x1.16x0.75x2.24x
Price / BookPrice ÷ Book value/share4.67x0.94x3.31x2.81x
Price / FCFMarket cap ÷ FCF14.78x20.88x17.31x
IQV leads this category, winning 3 of 6 comparable metrics.

Profitability & Efficiency

Evenly matched — IQV and PRA each lead in 3 of 9 comparable metrics.

IQV delivers a 22.1% return on equity — every $100 of shareholder capital generates $22 in annual profit, vs $-6 for CRL. PRA carries lower financial leverage with a 0.32x debt-to-equity ratio, signaling a more conservative balance sheet compared to IQV's 2.44x. On the Piotroski fundamental quality scale (0–9), UNH scores 6/9 vs PRA's 3/9, reflecting solid financial health.

MetricIQV logoIQVIQVIA Holdings In…PRA logoPRAProAssurance Corp…UNH logoUNHUnitedHealth Grou…CRL logoCRLCharles River Lab…
ROE (TTM)Return on equity+22.1%+5.0%+11.5%-5.7%
ROA (TTM)Return on assets+4.7%+1.2%+3.9%-2.5%
ROICReturn on invested capital+8.7%+3.2%+9.2%+6.3%
ROCEReturn on capital employed+11.0%+4.0%+9.7%+8.1%
Piotroski ScoreFundamental quality 0–94364
Debt / EquityFinancial leverage2.44x0.32x0.77x0.95x
Net DebtTotal debt minus cash$14.2B$399M$54.0B$2.9B
Cash & Equiv.Liquid assets$2.0B$36M$24.4B$214M
Total DebtShort + long-term debt$16.2B$435M$78.4B$3.1B
Interest CoverageEBIT ÷ Interest expense3.10x4.53x4.71x6.38x
Evenly matched — IQV and PRA each lead in 3 of 9 comparable metrics.

Total Returns (Dividends Reinvested)

UNH leads this category, winning 3 of 6 comparable metrics.

A $10,000 investment in UNH five years ago would be worth $9,743 today (with dividends reinvested), compared to $5,311 for CRL. Over the past 12 months, CRL leads with a +32.8% total return vs UNH's -3.2%. The 3-year compound annual growth rate (CAGR) favors PRA at 9.7% vs UNH's -7.1% — a key indicator of consistent wealth creation.

MetricIQV logoIQVIQVIA Holdings In…PRA logoPRAProAssurance Corp…UNH logoUNHUnitedHealth Grou…CRL logoCRLCharles River Lab…
YTD ReturnYear-to-date-20.7%+2.5%+10.6%-10.1%
1-Year ReturnPast 12 months+16.5%+7.2%-3.2%+32.8%
3-Year ReturnCumulative with dividends-5.9%+32.0%-19.9%-4.2%
5-Year ReturnCumulative with dividends-23.8%-3.2%-2.6%-46.9%
10-Year ReturnCumulative with dividends+166.5%-18.8%+220.6%+119.2%
CAGR (3Y)Annualised 3-year return-2.0%+9.7%-7.1%-1.4%
UNH leads this category, winning 3 of 6 comparable metrics.

Risk & Volatility

PRA leads this category, winning 2 of 2 comparable metrics.

PRA is the less volatile stock with a 0.05 beta — it tends to amplify market swings less than CRL's 1.52 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. PRA currently trades 99.0% from its 52-week high vs IQV's 72.3% drawdown — a narrower gap to the peak suggests stronger recent price momentum.

MetricIQV logoIQVIQVIA Holdings In…PRA logoPRAProAssurance Corp…UNH logoUNHUnitedHealth Grou…CRL logoCRLCharles River Lab…
Beta (5Y)Sensitivity to S&P 5001.33x0.05x0.59x1.52x
52-Week HighHighest price in past year$247.05$24.85$395.52$228.88
52-Week LowLowest price in past year$134.65$22.72$234.60$131.30
% of 52W HighCurrent price vs 52-week peak+72.3%+99.0%+93.5%+79.5%
RSI (14)Momentum oscillator 0–10058.548.475.957.2
Avg Volume (50D)Average daily shares traded1.6M793K7.9M806K
PRA leads this category, winning 2 of 2 comparable metrics.

Analyst Outlook

UNH leads this category, winning 1 of 1 comparable metric.

Analyst consensus: IQV as "Buy", PRA as "Hold", UNH as "Buy", CRL as "Buy". Consensus price targets imply 26.3% upside for IQV (target: $226) vs -25.5% for PRA (target: $18). UNH is the only dividend payer here at 2.35% yield — a key consideration for income-focused portfolios.

MetricIQV logoIQVIQVIA Holdings In…PRA logoPRAProAssurance Corp…UNH logoUNHUnitedHealth Grou…CRL logoCRLCharles River Lab…
Analyst RatingConsensus buy/hold/sellBuyHoldBuyBuy
Price TargetConsensus 12-month target$225.63$18.33$385.43$205.43
# AnalystsCovering analysts44115236
Dividend YieldAnnual dividend ÷ price+2.4%
Dividend StreakConsecutive years of raises20251
Dividend / ShareAnnual DPS$8.70
Buyback YieldShare repurchases ÷ mkt cap+4.1%0.0%+1.7%+4.0%
UNH leads this category, winning 1 of 1 comparable metric.
Key Takeaway

IQV leads in 2 of 6 categories (Income & Cash Flow, Valuation Metrics). UNH leads in 2 (Total Returns, Analyst Outlook). 1 tied.

Best OverallIQVIA Holdings Inc. (IQV)Leads 2 of 6 categories
Loading custom metrics...

IQV vs PRA vs UNH vs CRL: Key Questions Answered

10 questions · data-driven answers · updated daily

01

Is IQV or PRA or UNH or CRL a better buy right now?

For growth investors, UnitedHealth Group Incorporated (UNH) is the stronger pick with 11.

8% revenue growth year-over-year, versus -2. 7% for ProAssurance Corporation (PRA). IQVIA Holdings Inc. (IQV) offers the better valuation at 22. 8x trailing P/E (14. 1x forward), making it the more compelling value choice. Analysts rate IQVIA Holdings Inc. (IQV) a "Buy" — based on 44 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

02

Which has the better valuation — IQV or PRA or UNH or CRL?

On trailing P/E, IQVIA Holdings Inc.

(IQV) is the cheapest at 22. 8x versus UnitedHealth Group Incorporated at 27. 9x. On forward P/E, IQVIA Holdings Inc. is actually cheaper at 14. 1x.

03

Which is the better long-term investment — IQV or PRA or UNH or CRL?

Over the past 5 years, UnitedHealth Group Incorporated (UNH) delivered a total return of -2.

6%, compared to -46. 9% for Charles River Laboratories International, Inc. (CRL). Over 10 years, the gap is even starker: UNH returned +220. 6% versus PRA's -18. 8%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

04

Which is safer — IQV or PRA or UNH or CRL?

By beta (market sensitivity over 5 years), ProAssurance Corporation (PRA) is the lower-risk stock at 0.

05β versus Charles River Laboratories International, Inc. 's 1. 52β — meaning CRL is approximately 3064% more volatile than PRA relative to the S&P 500. On balance sheet safety, ProAssurance Corporation (PRA) carries a lower debt/equity ratio of 32% versus 2% for IQVIA Holdings Inc. — giving it more financial flexibility in a downturn.

05

Which is growing faster — IQV or PRA or UNH or CRL?

By revenue growth (latest reported year), UnitedHealth Group Incorporated (UNH) is pulling ahead at 11.

8% versus -2. 7% for ProAssurance Corporation (PRA). On earnings-per-share growth, the picture is similar: IQVIA Holdings Inc. grew EPS 4. 7% year-over-year, compared to -1555. 0% for Charles River Laboratories International, Inc.. Over a 3-year CAGR, UNH leads at 11. 4% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

06

Which has better profit margins — IQV or PRA or UNH or CRL?

IQVIA Holdings Inc.

(IQV) is the more profitable company, earning 8. 3% net margin versus -3. 6% for Charles River Laboratories International, Inc. — meaning it keeps 8. 3% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: IQV leads at 14. 0% versus 4. 2% for UNH. At the gross margin level — before operating expenses — PRA leads at 39. 4%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

07

Is IQV or PRA or UNH or CRL more undervalued right now?

On forward earnings alone, IQVIA Holdings Inc.

(IQV) trades at 14. 1x forward P/E versus 21. 8x for ProAssurance Corporation — 7. 7x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for IQV: 26. 3% to $225. 63.

08

Which pays a better dividend — IQV or PRA or UNH or CRL?

In this comparison, UNH (2.

4% yield) pays a dividend. IQV, PRA, CRL do not pay a meaningful dividend and should not be held primarily for income.

09

Is IQV or PRA or UNH or CRL better for a retirement portfolio?

For long-horizon retirement investors, UnitedHealth Group Incorporated (UNH) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0.

59), 2. 4% yield, +220. 6% 10Y return). Charles River Laboratories International, Inc. (CRL) carries a higher beta of 1. 52 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (UNH: +220. 6%, CRL: +119. 2%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

10

What are the main differences between IQV and PRA and UNH and CRL?

These companies operate in different sectors (IQV (Healthcare) and PRA (Financial Services) and UNH (Healthcare) and CRL (Healthcare)), which means they face different economic cycles, regulatory environments, and macro sensitivities — making direct comparison nuanced.

UNH pays a dividend while IQV, PRA, CRL do not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.

Find Stocks Like These

Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform all of them.

Stocks Like

IQV

Quality Business

  • Sector: Healthcare
  • Market Cap > $100B
  • Revenue Growth > 5%
  • Net Margin > 5%
Run This Screen
Stocks Like

PRA

Quality Business

  • Sector: Financial Services
  • Market Cap > $100B
  • Net Margin > 5%
Run This Screen
Stocks Like

UNH

Income & Dividend Stock

  • Sector: Healthcare
  • Market Cap > $100B
  • Dividend Yield > 0.9%
Run This Screen
Stocks Like

CRL

Quality Business

  • Sector: Healthcare
  • Market Cap > $100B
  • Gross Margin > 14%
Run This Screen
Custom Screen

Beat Both

Find stocks that outperform IQV and PRA and UNH and CRL on the metrics below

Revenue Growth>
%
(IQV: 8.4% · PRA: -2.0%)
Net Margin>
%
(IQV: 8.3% · PRA: 6.0%)
P/E Ratio<
x
(IQV: 22.8x · PRA: 24.9x)

You Might Also Compare

Based on how these companies actually compete and overlap — not just which sector they're filed under.